CapsoVision Inc. (CV) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

CapsoVision Inc. Scores 45 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The Fundamental Cash Engine pillar scores 8 out of 20, reflecting ROIC of -35% and an FCF yield of -6.22%, which signals that the business is currently consuming rather than generating cash relative to its market value. The Whale 13F Flow pillar scores 10 out of 20, indicating institutional accumulation and options positioning that are only moderately supportive. The Insider Conviction pillar scores 3 out of 20, the weakest reading in the rating, reflecting the SEC Form 4 and Congressional PTR cluster flow in the source data. The Macro Regime Fit pillar scores 10 out of 20, with a beta of 1.0 and sector sensitivity that offers no clear defensive cushion. The Forensic Balance Sheet pillar scores 14 out of 20, supported by an Altman Z-Score of 26, a Piotroski F-Score of 4 out of 9, and a Debt/Equity ratio of 0.5.

For a prospective investor evaluating the stock today, the upside case rests on the balance sheet and institutional flow rather than on operating cash generation, since the operating and net margins of -60% and the negative FCF are the dominant facts.94 cannot be tested against earnings. The stock's 52-week range of $4.5 to $15.37 shows a large drawdown from the high, which the Wyckoff Distribution headline in the news feed characterizes as distribution. The second-order implication is that the rating's weakest links, insider conviction and cash generation, are the signals most likely to determine whether the balance-sheet strength can be converted into shareholder value. This analysis is educational and is not personalized financial advice.

CapsoVision Inc. (CV) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry..4B. Per the recent news feed, the company's capsule platform targets cancer screening.9% and revenue of $13.6M for FY 2025 are the only commercial indicators available.

Revenue rose from $11.8M in FY 2024 to $13.6M in FY 2025, while operating losses widened from -$19.9M to -$25.5M. Per the market data, the operating margin and net margin are both -60% and ROIC is -35%. The Altman Z-Score is 26 and the Piotroski F-Score is 4 out of 9, with a Debt/Equity ratio of 0.5.

• 🐂 Primary Bull Case: The forensic balance sheet scores 14 of 20 with a 26 Altman Z-Score and 0.5 Debt/Equity, indicating solvency strength despite heavy operating losses. With Fundamental Cash Engine at 8/20 (ROIC -35.0%, FCF yield -6.22%) and Institutional Whale Flow at 8/20, sustained execution supports upside toward the top of the $4.50 – $15.37 52-week range.
• 🐻 Primary Bear Case: ROIC of -35%, an FCF yield of -6.22%, and operating margin of -60% show the business is consuming cash, and the insider conviction pillar scores only 3 of 20. Investors must weigh current valuation against -60.0% operating margins and a 1.00 macro beta if sector demand softens.

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — The only sector context provided is the Health Care classification and the Electromedical & Electrotherapeutic Apparatus industry.

• Key Question #1: What are the cash and debt balances, which are listed as N/A in both reported periods, and how long does current cash cover the -$23.0M FY 2025 free cash flow burn?
• Key Question #2: What are the EPS, P/E, and EV/EBITDA figures that would allow the $6.94 price to be tested against earnings?
• Key Question #3: Which upstream suppliers, manufacturers, or regulatory milestones does the capsule platform depend on?